United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Wednesday, November 11th. The shares were sold at an average price of $593.99, for a total transaction of $5,642,905.00. Following the completion of the sale, the chief executive officer owned 324,443 shares in the company, valued at $192,715,897.57. This represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
United Therapeutics Price Performance
United Therapeutics stock opened at $593.31 on Friday. The firm has a market capitalization of $25.27 billion, a price-to-earnings ratio of 22.39, a PEG ratio of 3.99 and a beta of 0.49. The company's 50 day simple moving average is $540.58 and its 200 day simple moving average is $535.80. United Therapeutics Corporation has a fifty-two week low of $455.63 and a fifty-two week high of $614.23.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.01 by ($0.30). The firm had revenue of $832.50 million during the quarter, compared to the consensus estimate of $781.14 million. United Therapeutics had a net margin of 38.61% and a return on equity of 19.18%. The firm's revenue for the quarter was up 4.1% on a year-over-year basis. During the same period in the previous year, the company posted $7.16 EPS. As a group, analysts predict that United Therapeutics Corporation will post 24.90 EPS for the current fiscal year.
United Therapeutics declared that its Board of Directors has authorized a share repurchase program on Thursday, October 22nd that permits the company to buy back $2 billion in shares. This buyback authorization permits the biotechnology company to buy up to 8.3% of its shares through open market purchases. Share buyback programs are typically an indication that the company's board believes its shares are undervalued.
Analysts Set New Price Targets
A number of analysts recently commented on UTHR shares. UBS Group set a $725.00 price objective on shares of United Therapeutics in a research report on Monday, October 19th. HC Wainwright started coverage on United Therapeutics in a report on Monday. They set a "buy" rating and a $660.00 target price on the stock. Royal Bank Of Canada boosted their target price on United Therapeutics from $697.00 to $725.00 and gave the company an "outperform" rating in a research note on Thursday, November 5th. Leerink Partners increased their price target on United Therapeutics from $685.00 to $725.00 and gave the stock an "outperform" rating in a report on Monday, October 19th. Finally, Weiss Ratings downgraded United Therapeutics from a "buy (b-)" rating to a "hold (c+)" rating in a report on Monday. Twelve investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $676.40.
View Our Latest Analysis on UTHR
Institutional Investors Weigh In On United Therapeutics
Several large investors have recently made changes to their positions in UTHR. BlackRock Inc. acquired a new stake in shares of United Therapeutics during the second quarter worth $2,868,735,000. Jupiter Topco LLC acquired a new position in United Therapeutics in the 2nd quarter worth $450,140,000. Bank of New York Mellon Corp acquired a new position in United Therapeutics in the 2nd quarter worth $159,522,000. Caisse de depot et placement du Quebec acquired a new position in United Therapeutics in the 2nd quarter worth $154,304,000. Finally, Legal & General Group Plc bought a new position in United Therapeutics during the 2nd quarter worth about $112,209,000. Institutional investors own 94.08% of the company's stock.
Latest United Therapeutics News
Here's some of the latest news about UTHR:
- Positive Sentiment: HC Wainwright initiated coverage with a Buy rating and a $660 price target. Its forecasts point to rising EPS, from $27.46 in FY2026 to $53.67 in FY2030, suggesting expectations for substantial longer-term earnings growth. HC Wainwright coverage article
- Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares for about $5.64 million, reducing her direct stake by 2.84%; she still owns about 324,443 shares. Director Christopher Patusky also sold 1,210 shares for $701,800, a 36.12% reduction in his position. Insider selling can create a near-term sentiment overhang, although it does not by itself indicate a change in the company’s outlook. CEO sale report Director sale report
About United Therapeutics
(
Get Free Report)
United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
